Shanghai ZhenGe Biotech has completed a USD100 million series C financing round led by Goldman Sachs Asset Management and Sofina.

Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital, also invested in the round with proceeds set to be used to strengthen ZhenGe Biotech’s global R & D capabilities and expand its Good Manufacturing Practice (GMP) manufacturing capacity to better meet demand from domestic and international clients. To date, the Company has raised a total of USD225 million.